Borstnar S - Search Results

1

Axillary ultrasound for predicting response to neoadjuvant treatment in breast cancer patients-a single institution experience.

Pislar N, Gasljevic G, Music MM, Borstnar S, Zgajnar J, Perhavec A. Pislar N, et al. Among authors: borstnar s. World J Surg Oncol. 2023 Sep 16;21(1):292. doi: 10.1186/s12957-023-03174-8. World J Surg Oncol. 2023. PMID: 37715188 Free PMC article.

2

Triple negative breast cancer - prognostic factors and survival.

Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Ovcaricek T, et al. Among authors: borstnar s. Radiol Oncol. 2011 Mar;45(1):46-52. doi: 10.2478/v10019-010-0054-4. Epub 2010 Dec 31. Radiol Oncol. 2011. PMID: 22933934 Free PMC article.

3

Intraoperative Touch Imprint Cytology in Breast Cancer Patients After Neoadjuvant Chemotherapy.

Hadalin V, Pislar N, Borstnar S, Matos E, Kovac A, Dobovisek L, Cankar K, Perhavec A. Hadalin V, et al. Among authors: borstnar s. Clin Breast Cancer. 2022 Jun;22(4):e597-e603. doi: 10.1016/j.clbc.2021.12.013. Epub 2022 Jan 5. Clin Breast Cancer. 2022. PMID: 35086763

4

Complete response in the axilla and the non-triple negative subtype are favourable prognostic factors for survival outcomes in inflammatory breast cancer.

Kuhar CG, Borštnar S, Gazić B, Matos E. Kuhar CG, et al. Among authors: borstnar s. Breast. 2023 Jun;69:481-490. doi: 10.1016/j.breast.2023.01.011. Epub 2023 Jan 24. Breast. 2023. PMID: 36740512 Free PMC article.

5

Cannabinoids and triple-negative breast cancer treatment.

Dobovišek L, Borštnar S, Debeljak N, Kranjc Brezar S. Dobovišek L, et al. Among authors: borstnar s. Front Immunol. 2024 Aug 8;15:1386548. doi: 10.3389/fimmu.2024.1386548. eCollection 2024. Front Immunol. 2024. PMID: 39176080 Free PMC article. Review.

6

Invasive bladder cancer: our experience with bladder sparing approach.

Cervek J, Cufer T, Zakotnik B, Kragelj B, Borstnar S, Matos T, Zumer-Pregelj M. Cervek J, et al. Among authors: borstnar s. Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):273-8. doi: 10.1016/s0360-3016(98)00013-3. Int J Radiat Oncol Biol Phys. 1998. PMID: 9607341

7

Prognostic value of plasminogen activator inhibitors in breast cancer.

Borstnar S, Vrhovec I, Cufer T. Borstnar S, et al. Int J Biol Markers. 2002 Apr-Jun;17(2):96-103. doi: 10.1177/172460080201700204. Int J Biol Markers. 2002. PMID: 12113588 Free article.

8

Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.

Borstnar S, Vrhovec I, Svetic B, Cufer T. Borstnar S, et al. Clin Breast Cancer. 2002 Jun;3(2):138-46. doi: 10.3816/CBC.2002.n.018. Clin Breast Cancer. 2002. PMID: 12123538

9

Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer.

Cufer T, Borstnar S, Vrhovec I. Cufer T, et al. Among authors: borstnar s. Int J Biol Markers. 2003 Apr-Jun;18(2):106-15. doi: 10.1177/172460080301800203. Int J Biol Markers. 2003. PMID: 12841679 Free article.

10

Prognostic and predictive value of cathepsins D and L in operable breast cancer patients.

Jagodic M, Vrhovec I, Borstnar S, Cufer T. Jagodic M, et al. Among authors: borstnar s. Neoplasma. 2005;52(1):1-9. Neoplasma. 2005. PMID: 15739019 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters